New data for HCV genotype 4 patients with simeprevir- and sofosbuvir-based regimens
Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver Congress 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon ...
Apr 12, 2014
0
0